Search our Database of Scientific Publications and Authors

I’m looking for a

    11398 results match your criteria Cutaneous T-Cell Lymphoma

    1 OF 228

    Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case Study.
    Acta Derm Venereol 2018 Apr 24. Epub 2018 Apr 24.
    Department of Dermatology, University Hospital Zurich, CH-8091 Zurich, Switzerland.
    Rare T- or NK-cell lymphomas with cutaneous manifestation may display a highly aggressive clinical course and major diagnostic/therapeutic challenges. This report describes our experiences with different lymphomas of this rare category and the therapeutic options used. This retrospective, descriptive, monocentric, cross-sectional case study, identified 4 rare aggressive T-/NK-cell lymphomas with manifestation in the skin, which were diagnosed in a tertiary care centre over a period of 4 years. Read More

    Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response.
    JAAD Case Rep 2018 May 31;4(4):305-309. Epub 2018 Mar 31.
    Department of Dermatology, St. Joseph Mercy Hospital, Ann Arbor, Michigan.
    We report a case of histologically confirmed primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) that subsequently underwent spontaneous regression in the absence of systemic treatment. The case showed an atypical lymphoid infiltrate that was CD20 and MUM-1 and CD10. A subsequent biopsy of the spontaneously regressed lesion showed fibrosis associated with a lymphocytic infiltrate comprising reactive T cells. Read More

    Transcript-indexed ATAC-seq for precision immune profiling.
    Nat Med 2018 Apr 23. Epub 2018 Apr 23.
    Center for Personal Dynamic Regulomes, Stanford University School of Medicine, Stanford, CA, USA.
    T cells create vast amounts of diversity in the genes that encode their T cell receptors (TCRs), which enables individual clones to recognize specific peptide-major histocompatibility complex (MHC) ligands. Here we combined sequencing of the TCR-encoding genes with assay for transposase-accessible chromatin with sequencing (ATAC-seq) analysis at the single-cell level to provide information on the TCR specificity and epigenomic state of individual T cells. By using this approach, termed transcript-indexed ATAC-seq (T-ATAC-seq), we identified epigenomic signatures in immortalized leukemic T cells, primary human T cells from healthy volunteers and primary leukemic T cells from patient samples. Read More

    Photodynamic therapy as an alternative treatment for mycosis fungoides: a systemic review and meta-analysis.
    G Ital Dermatol Venereol 2018 Apr 19. Epub 2018 Apr 19.
    Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland -
    Mycosis fungoides is the most common Cutaneous T cell lymphoma. Selection of appropriate treatment for mycosis fungoides is based on prognostic factors and overall clinical stage at diagnosis. In the past decade, clinical success has been reported using photodynamic therapy as an alternative target-specific therapy to treat mycosis fungoides. Read More

    Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy.
    Case Rep Oncol 2018 Jan-Apr;11(1):212-215. Epub 2018 Mar 28.
    Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Bexarotene is a third-generation retinoid X receptor-selective retinoid that is widely used for the early treatment of advanced-stage cutaneous T-cell lymphomas. In this report, we describe a case of successful treatment of advanced primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) with oral bexarotene monotherapy. After the administration of oral bexarotene at a dose of 300 mg/m/day, all skin lesions and lymph nodes regressed, and complete remission was achieved for 1 year. Read More

    A Microbiota-Dependent, STAT3-Driven Mouse Model of Cutaneous T-Cell Lymphoma.
    J Invest Dermatol 2018 May;138(5):1022-1026
    Department of Dermatology, University of California Davis, School of Medicine, Sacramento, California. Electronic address:
    In recent years, much has been learned about the molecular genetics of cutaneous T-cell lymphomas. Fanok et al. (2018) translate knowledge from systematic genomic and transcriptomic analyses to develop a mouse model that tests the hypothesis that activated STAT3 in CD4 T cells may be a driver of cutaneous T-cell lymphomas. Read More

    The First Year of the AEVD Primary Cutaneous Lymphoma Registry.
    Actas Dermosifiliogr 2018 Apr 18. Epub 2018 Apr 18.
    Servicio de Dermatología, Hospital Universitario 12 de Octubre, Institute i+12, Medical School. Universidad Complutense, ONCOCIBER, Madrid, España.
    Background And Objective: Primary cutaneous lymphomas are uncommon. This article describes the Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV) and reports on the results from the first year.

    Patients And Methods: Disease registry for patients with primary cutaneous lymphoma. Read More

    Ethnic disparity in primary cutaneous CD30 T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer Database.
    Br J Haematol 2018 Apr 20. Epub 2018 Apr 20.
    The Second Xiangya Hospital, Central South University, Department of Dermatology, Changsha, Hunan, China.
    Primary cutaneous CD30 T cell lymphoproliferative disorders (PCLPD), the second most common type of primary cutaneous T cell lymphomas, accounts for approximately 25-30% of cutaneous T-cell lymphoma cases. However, only small retrospective studies have been reported. We aimed to identify prognostic factors and evaluate the overall survival (OS) of patients with PCLPD stratified by ethnicity. Read More

    Epigenetically Enhanced PDT (ePDT) Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of CTCL.
    Photochem Photobiol 2018 Apr 20. Epub 2018 Apr 20.
    University of Wisconsin, Department of Dermatology, Madison, WI.
    Aminolevulinate-based photodynamic therapy (ALA-PDT) selectively eliminates diseased tissues primarily through the induction of intrinsic apoptotic pathway. ALA-PDT is a first-line therapy for actinic keratosis, however, it is less effective for cutaneous T-cell lymphoma (CTCL). We have previously demonstrated that the resistance of CTCL to apoptosis correlates with decreased expression of death receptors such as FAS, and that methotrexate functions as an epigenetic regulator that re-establishes the susceptibility of CTCL to extrinsic pathway apoptosis. Read More

    [Primary cutaneous CD30+ T-cell lymphoproliferation during treatment with fingolimod: Case report and literature review].
    Ann Dermatol Venereol 2018 Apr 16. Epub 2018 Apr 16.
    Service de dermatologie et d'allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Faculté de médecine, Sorbonne université, 75013 Paris, France. Electronic address:
    Background: Fingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described. Read More

    Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
    Blood Adv 2018 Apr;2(8):871-876
    Memorial Sloan Kettering Cancer Center, New York, NY.
    Ibrutinib has previously been shown to inhibit Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell malignancies. Whether ibrutinib inhibition of ITK can lead to clinical response in T-cell malignancies is unknown. Read More

    Lymphomatoid papulosis presenting as a rash in a patient with HIV infection.
    Int J STD AIDS 2018 Jan 1:956462418767183. Epub 2018 Jan 1.
    3 Department of Histopathology, 97609 University Hospital of Wales , Cardiff, UK.
    A 43-year-old Malaysian man with well-controlled HIV infection on combination antiretroviral therapy presented with a six-week history of a widespread rash. The patient was otherwise well but was developing new lesions on a daily basis. Referral to Dermatology instigated punch biopsies, which revealed a diagnosis of lymphomatoid papulosis type A. Read More

    Bronchial brush cytology of primary anaplastic large cell lymphoma of lung.
    Diagn Cytopathol 2018 Apr 16. Epub 2018 Apr 16.
    Department of Pulmonary Medicine, Jawaharlal Institute of Post Graduate Medical Education and Research, Dhanwantri Nagar, Puducherry 605006, India.
    Primary pulmonary lymphoma is defined as clonal lymphoid proliferation affecting one or both lungs in a patient with no extrapulmonary involvement at the time of diagnosis or during the subsequent 3 months. Anaplastic large cell lymphoma (ALCL) is a rare T-cell neoplasm which occurs as two distinct clinical entities-cutaneous and systemic variant. Primary lung involvement is extremely uncommon. Read More

    Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016.
    Ann Dermatol Venereol 2018 Apr 13. Epub 2018 Apr 13.
    Dermatology department, hôpital Saint-Louis, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; Inserm Unité 976, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, Sorbonne-Paris-Cité, 75000 Paris, France.
    Introduction: Adult T-cell leukemia/lymphoma (ATLL) is a hematological malignancy associated with chronic HTLV-1 infection.

    Aim: To describe skin lesions in ATLL.

    Methods: A descriptive, retrospective study between 1996 and 2016, including all patients diagnosed with ATLL at Saint-Louis Hospital (Paris, France). Read More

    Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides.
    Radiat Oncol 2018 Apr 13;13(1):67. Epub 2018 Apr 13.
    Department of Human Oncology, University of Wisconsin, Madison, WI, USA.
    Background: Total skin electron beam therapy (TSEBT) is an effective treatment in mycosis fungoides. Total skin helical tomotherapy (TSHT) may be an alternative to TSEBT and may offer several dosimetric and treatment advantages. There are currently very few published treatment results using TSHT in place of TSEBT for treatment of mycosis fungoides. Read More

    Hydroa vacciniforme-like cutaneous T-cell lymphoma in a child: A case report.
    Medicine (Baltimore) 2018 04;97(15):e0319
    Department of Pediatrics, West China Second University Hospital.
    Rationale: Hydroa vacciniforme (HV)-like T-cell lymphoma is a rare malignancy in childhood associated with Epstein-Barr virus infection.

    Patient Concerns: A 6-year old girl presented with complaint of 3-year history of recurrent skin lesions, 3 months of fever accompanied by cough for 8 days.

    Diagnoses: Skin biopsy revealed a HV-like lymphoma presentation and positive signals of EBER were detected by in situ hybridization. Read More

    The efficacy and safety of phototherapy in geriatric patients: a retrospective study.
    An Bras Dermatol 2018 Jan-Feb;93(1):33-38
    Department of Dermatology, Faculty of Medicine, Eskisehir Osmangazi University, Eskişehir, Turkey.
    Background: While phototherapy is a well-established treatment for many dermatoses, data from the literature regarding its use in elderly patients are quite limited.

    Objective: In this study, we aimed to determine the phototherapy indications in geriatric patients and to evaluate the effectiveness and reliability of phototherapy in this group.

    Methods: This study included 95 patients of 65 years of age and older who were treated in our phototherapy unit between 2006 and 2015. Read More

    Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma.
    J Clin Pathol 2018 Apr 10. Epub 2018 Apr 10.
    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
    Aims: Substantial clinicopathological overlap exists between cutaneous T-cell lymphoma (CTCL) and benign conditions, leading to diagnostic difficulties. We sought to delineate the utility of high-throughput sequencing (HTS) across a spectrum of histological findings in CTCL and reactive mimics.

    Methods: One hundred skin biopsies obtained for clinical concern for CTCL were identified, comprising 25 cases each from four histological categories: 'definitive CTCL', 'atypical lymphoid infiltrate, concerning for CTCL', 'atypical lymphoid infiltrate, favour reactive' or 'reactive lymphoid infiltrate'. Read More

    The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).
    Cancers (Basel) 2018 Apr 4;10(4). Epub 2018 Apr 4.
    Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076 Tübingen, Germany.
    Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell lymphoproliferations that share morphological and immunophenotypical features, namely strong CD30 expression and variable loss of T-cell markers, but differ in clinical presentation and prognosis. The recognition of anaplastic lymphoma kinase (ALK) fusion proteins as a result of chromosomal translocations or inversions was the starting point for the distinction of different subgroups of ALCL. According to their distinct clinical settings and molecular findings, the 2016 revised World Health Organization (WHO) classification recognizes four different entities: systemic ALK-positive ALCL (ALK+ ALCL), systemic ALK-negative ALCL (ALK− ALCL), primary cutaneous ALCL (pC-ALCL), and breast implant-associated ALCL (BI-ALCL), the latter included as a provisional entity. Read More

    The Importance of Excluding Cutaneous T-Cell Lymphomas in Patients with a Working Diagnosis of Papuloerythroderma of Ofuji: A Case Series.
    Case Rep Dermatol 2018 Jan-Apr;10(1):46-54. Epub 2018 Feb 21.
    Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada.
    Papuloerythroderma of Ofuji (PEO) is an erythroderma-like eruption with flat-topped papules that spare the skin folds (a "deck-chair sign" finding). Many infections, medications, and systemic diseases have been associated with PEO, including cutaneous T-cell lymphomas (CTCL). The relationship between the clinical presentation of PEO and CTCL remains poorly elucidated. Read More

    Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression.
    Int J Dermatol 2018 Mar 30. Epub 2018 Mar 30.
    Department of Dermatology, University of São Paulo Medical School, São Paulo, Brazil.
    Background: Folliculotropic mycosis fungoides (FMF) is a cutaneous T-cell lymphoma mainly affecting the hair follicle, which seems to represent a place of immune privilege phenomenon.

    Objectives: To explore a possible role of immune privilege (IP) in FMF analyzing the major histocompatibility complex (MHC) expression.

    Methods: Immunohistochemistry for HLA-G and MHC-II was performed to formalin-fixed paraffin-embedded cutaneous skin biopsies of FMF patients (n = 43), conventional mycosis fungoides (CMF; n = 13), alopecia areata (AA; n = 13), and normal scalp skin (NS; n = 12). Read More

    The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
    J Dermatol Sci 2018 Mar 15. Epub 2018 Mar 15.
    Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA; Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, 35294, USA. Electronic address:
    Background: Bexarotene (Targretin) is currently the only FDA approved retinoid X receptor (RXR) -selective agonist for the treatment of cutaneous T-cell lymphomas (CTCLs). The main side effects of bexarotene are hypothyroidism and elevation of serum triglycerides (TGs). The novel RXR ligand, 9-cis UAB30 (UAB30) does not elevate serum TGs or induce hypothyroidism in normal subjects. Read More

    [Extracorporeal photopheresis].
    Rev Med Suisse 2018 Mar;14(600):699-702
    Service de dermatologie et vénéréologie, HUG, 1211 Genève 14.
    During the treatment of extracorporeal photopheresis (ECP), white blood cells are collected by apheresis and exposed to ultraviolet A after incubation with 8-methoxypsoralen. Although ECP was first developed for cutaneous T cell lymphoma, it has shown promising efficacy in a number of other serious conditions, like acute and chronic graft-versus-host disease, lung and cardiac transplant rejection and other autoimmune diseases. The ECP has been used for thirty years in some specialized centers but remains unknown to most of the physicians. Read More

    American council on ECP (ACE): Why now?
    J Clin Apher 2018 Mar 25. Epub 2018 Mar 25.
    Department of Pediatric Hematology/Oncology/Neuro-oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois.
    Stimulated by the scientific progress in deciphering the principal elements contributing to the clinical efficacy of extracorporeal photochemotherapy (ECP), the American Council on ECP (ACE) was formed, under the auspices of the American Society for Apheresis (ASFA), to develop a field-guiding Consensus Report. ACE is composed of thirty nationally recognized ECP experts, clinically spanning cancer, transplantation, and autoimmunity and scientifically bridging immunology, bioengineering, and hematology. The two-day meeting took place in Manhattan, April 13-14, 2017, and unanimous consensus on nine pivotal points is herein reported. Read More

    Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma.
    J Eur Acad Dermatol Venereol 2018 Mar 24. Epub 2018 Mar 24.
    Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence Medical School, Florence, Italy.
    Peripheral T-cell lymphomas not otherwise specified (PTCLs-NOS) have been defined as a kind of "Pandora's box", because of the broad morphologic spectrum, which features a prevalent nodal involvement and an aggressive, yet non-specific clinical course . PTCLs-NOS usually have a nodal presentation, while a skin spread occurs in approximately 20% of cases being regarded as a worse prognostic factor . PTCLs-NOS featuring skin lesions present at least six months before a hypothetical systemic involvement are regarded as a separate entity, named primary cutaneous PTCLs-NOS (PC-PTCLs-NOS) . Read More

    Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
    Curr Oncol Rep 2018 Mar 23;20(4):32. Epub 2018 Mar 23.
    Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.
    Purpose Of Review: Cutaneous T-cell lymphoma (CTCL) is a rare form of non-Hodgkin lymphoma. Globally, the most common subtypes of CTCL are mycosis fungoides and Sézary syndrome. CTCL can confer significant morbidity and even mortality in advanced disease. Read More

    Development of New Bexarotene-loaded Mesoporous Silica Systems for Topical Pharmaceutical Formulations.
    Acta Chim Slov 2018 Mar;65(1):97-107
    The present study reports the first time use of MCM-41 mesoporous silica as highly efficient carrier for bexarotene - an antineoplastic agent specific for cutaneous T-cell lymphoma treatment. Bexarotene is highly toxic and poor-water soluble, having low bioavailability in the conventional pharmaceutical forms. Comparative uptake of bexarotene on amino-functionalized silica host at various functionalization degrees is discussed in details taking into account all structural features, of matrix as well as properties of the drug molecules. Read More

    A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).
    Clin Epidemiol 2018 13;10:299-310. Epub 2018 Mar 13.
    Department of Epidemiology, RTI Health Solutions, Barcelona, Spain.
    Background: There is a concern that topical tacrolimus and pimecrolimus, indicated for second-line treatment of atopic dermatitis, may increase the risk of lymphoma and skin cancer, particularly in children.

    Objective: The aim of this study was to compare incidence rates (IRs) of lymphoma and skin cancer between new users of topical tacrolimus or pimecrolimus and users of moderate- to high-potency topical corticosteroids (TCSs) and untreated subjects.

    Methods: This is a multicenter cohort study with frequency matching by strata of propensity scores in population databases in the Netherlands, Denmark, Sweden, and the UK. Read More

    microRNA signatures in diagnosis and prognosis of cutaneous T cell lymphoma.
    J Invest Dermatol 2018 Mar 17. Epub 2018 Mar 17.
    Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China. Electronic address:
    Cutaneous T cell lymphoma (CTCL) can have clinical and histological features resembling benign inflammatory dermatosis (BID) and can be difficult to diagnose. Very limited biomarkers are available for CTCL prognosis. We aimed to identify microRNA (miR) signatures to facilitate diagnostic and prognostic evaluations of CTCL. Read More

    A case of HTLV-1 associated adult T-cell lymphoma presenting with cutaneous lesions and tropical spastic paresis.
    Intractable Rare Dis Res 2018 Feb;7(1):61-64
    Department of Hematology/Oncology, JFK Medical Center, Atlantis, Fl, USA.
    Adult T cell lymphoma (ATL), is a peripheral T cell neoplasm associated with infection by human T-lymphotropic virus (HTLV). This is a case of a 28-year-old lady who presented with back pain for the past month and recent onset weakness in her lower extremities bilaterally. She has a history of T-cell lymphoma secondary to HTLV-1 under remission since 2014 and systemic lupus erythematosus complicated by lupus nephritis. Read More

    Cutaneous non-epitheliotropic T-cell lymphoma associated with a fracture site in a cat.
    JFMS Open Rep 2018 Jan-Jun;4(1):2055116918760357. Epub 2018 Mar 9.
    Victorian Animal Cancer Care, Box Hill South, Victoria, Australia.
    Case Summary: A 7-year-old male neutered domestic shorthair cat presented for investigation of a swelling over the right forelimb. Radiographs of the right forelimb revealed significant lysis and soft tissue swelling surrounding a previously implanted surgical plate, used to repair a fracture of the distal radius 5 years prior. The implant was removed, and a biopsy was collected. Read More

    Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics.
    Adv Cancer Res 2018 1;138:183-211. Epub 2018 Mar 1.
    Medical University of South Carolina, College of Pharmacy, Charleston, SC, United States. Electronic address:
    Since the identification and cloning of human histone deacetylases (HDACs) and the rapid approval of vorinostat (Zolinza®) for the treatment of cutaneous T-cell lymphoma, the field of HDAC biology has met many initial successes. However, many challenges remain due to the complexity involved in the lysine posttranslational modifications, epigenetic transcription regulation, and nonepigenetic cellular signaling cascades. In this chapter, we will: review the discovery of the first HDAC inhibitor and present discussion regarding the future of next-generation HDAC inhibitors, give an overview of different classes of HDACs and their differences in lysine deacylation activity, discuss different classes of HDAC inhibitors and their HDAC isozyme preferences, and review HDAC inhibitors' preclinical studies, their clinical trials, their pharmacokinetic challenges, and future direction. Read More

    Successful Cord Blood Stem Cell Transplantation for Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated with Cerebral Infiltration.
    Intern Med 2018 Mar 9. Epub 2018 Mar 9.
    Department of Hematology and Rheumatology, Tohoku University Hospital, Japan.
    A 16-year-old boy, who had been initially examined for bilateral blepharedema and slight eruption, presented with rapidly deteriorating symptoms in associating with headache and consciousness disturbance. He was diagnosed to have primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (PCAE-CTL) by a biopsy of the skin and brain. After whole-brain radiation and some courses of chemotherapy, cord blood transplantation was performed with myeloablative conditioning. Read More

    [Romidepsin (Istodax for intravenous injection 10 mg): pharmacokinetics, pharmacodynamics and clinical study outcome].
    Nihon Yakurigaku Zasshi 2018;151(3):122-129
    R&D, Medical Affairs, Celgene K. K.
    Romidepsin (Brand name: ISTODAX for Injection 10 mg) is a novel antitumor drug that inhibits histone deacetylase (HDAC). Romidepsin strongly inhibited class I HDAC activity in vitro and demonstrated a strong antitumor activity against human tumor cell line xenograft in vivo. Based on its demonstrated efficacy against T-cell lymphoma in early clinical studies, multicenter phase II clinical studies in overseas with romidepsin were conducted in patients with cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), followed by approval for the treatment of CTCL and PTCL in the U. Read More

    Emerging roles of bexarotene in the prevention, treatment and anti-drug resistance of cancers.
    Expert Rev Anticancer Ther 2018 May 20;18(5):487-499. Epub 2018 Mar 20.
    a Department of Urology and Chawnshang Chang Liver Cancer Center , Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University , Hangzhou , China.
    Introduction: Retinoic acid X receptors play key roles in tumor cell proliferation, differentiation, apoptosis and angiogenesis via transcriptional regulation. Bexarotene is a specific RXRs agonist which has been granted by FDA approval for the clinical treatment of cutaneous T cell lymphoma (CTCL). Its cancer prevention and treatment potentials in various tumors have been under investigation over the past decade. Read More

    Update on the Treatment of Anaplastic Large Cell Lymphoma.
    Curr Hematol Malig Rep 2018 Apr;13(2):135-141
    Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, M1286, Box 0324, San Francisco, CA, 94143-0324, USA.
    Purpose Of Review: Given the rarity of anaplastic large cell lymphoma (ALCL), studies evaluating new therapies have typically grouped ALCL together with other peripheral T cell lymphomas (PTCL). Thus, the treatment paradigm for ALCL largely mirrors that of PTCL in general. In this review, we discuss the current standard of care as well as emerging therapies, including antibody-based drugs, in systemic ALCL as well as primary cutaneous and breast implant-associated ALCL. Read More

    Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy.
    Oncotarget 2018 Feb 3;9(11):9766-9775. Epub 2018 Jan 3.
    Hematology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
    The clinical outcome of T-cell non-Hodgkin lymphoma (NHL) is poor and innovative treatments are needed. Tenascin-C is a large extracellular glycoprotein not expressed under physiological conditions, but overexpressed in cancer. Aim of the study was to evaluate tenascin-C expression within pathologic tissue of T-cell NHL and determine its clinical significance. Read More

    Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy.
    Case Rep Oncol 2018 Jan-Apr;11(1):29-32. Epub 2018 Jan 16.
    Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
    Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47. Read More

    Large-Cell Transformed Mycosis Fungoides Coexisting with Mycosis Fungoides Bullosa: A Case Report and Review of the Literature.
    Case Rep Dermatol 2017 Sep-Dec;9(3):243-248. Epub 2017 Nov 27.
    Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
    Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Both large-cell transformed mycosis fungoides and mycosis fungoides bullosa are rare presentations and predict unfavorable prognosis. We report the case of a 61-year-old woman who presented with generalized erythematous scaly annular plaques, and histopathology confirmed the diagnosis of mycosis fungoides. Read More

    Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma.
    Leukemia 2018 Feb 22. Epub 2018 Feb 22.
    Stem Cells and Cancer Research Laboratory, CIBERONC, Institut Hospital del Mar Investigacions Mèdiques (IMIM), 08003, Barcelona, Spain.
    Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced forms of the disease (namely mycosis fungoides and the leukemic variant, Sézary syndrome). Molecular events leading to CTCL progression are heterogeneous, however recent DNA and RNA sequencing studies highlighted the importance of NF-κB and β-catenin pathways. We here show that the kinase TAK1, known as essential in B-cell lymphoma, is constitutively activated in CTCL cells, but tempered by the MYPT1/PP1 phosphatase complex. Read More

    SATB1 Defines a Subtype of Cutaneous CD30 Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile.
    J Invest Dermatol 2018 Mar 3. Epub 2018 Mar 3.
    Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. Electronic address:
    Cutaneous CD30 lymphoproliferative disorders (LPDs), including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma, comprise the second most common group of cutaneous T-cell lymphomas. Previously, we reported that special SATB1, a thymocyte-specific chromatin organizer, was overexpressed and promoted malignant T-cell proliferation in a portion of CD30 LPDs. Here, we investigated the expression pattern of SATB1 in CD30 LPDs with a large cohort of patient samples, and examined the potential of SATB1 as a molecular marker to classify CD30 LPDs with differential clinicopathological behaviors. Read More

    Cutaneous T-Cell Lymphoma, a Novel Manifestation of PDGFRA-Rearranged Neoplasm.
    Am J Dermatopathol 2018 Feb 21. Epub 2018 Feb 21.
    Division of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, IL.
    Patients with PDGFRA-rearranged hematopoietic neoplasms typically present with chronic eosinophilic leukemia and rarely with acute myeloid leukemia or T-lymphoblastic lymphoma. However, mature T-cell lymphoma has not been previously associated with PDGFRA aberrations. We report a patient who presented with simultaneous T-lymphoblastic lymphoma, focal myeloid proliferation, and cutaneous cytotoxic T-cell lymphoma refractory to chemotherapy. Read More

    Results of radiotherapy in minimal stage mycosis fungoides: a reappraisal after ten years.
    G Ital Dermatol Venereol 2018 Feb 26. Epub 2018 Feb 26.
    Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy.
    Background: Mycosis Fungoides (MF) is the most common cutaneous T cell lymphoma, accounting for 54-72 % of cases. When it presents as solitary or oligolesional picture, radiotherapy is considered potentially curative. To verify this we decided to evaluate the outcome in 15 patients studied in the period 1990-2007 after ten years. Read More

    Violet - Colored Inguinal Located Cutaneous Tumour?
    Open Access Maced J Med Sci 2018 Jan 13;6(1):137-138. Epub 2018 Jan 13.
    "Onkoderma"- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria.
    Anaplastic large cell lymphoma (ALCL) represents an aggressive CD30 - positive T cell lymphoma, as it is the second most common T cell lymphoma and 2% to 5% of all non - Hodgkin lymphomas. The cutaneous involvement can be primary or secondary within systemic ALCL, resembling inflammatory and other neoplastic lesions both clinically and cytologically. Various pigmented cutaneous tumours with a different origin, cutaneous metastasis and B-cell lymphoma must be carefully considered in the differential diagnostic plan. Read More

    1 OF 228